

7
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Stefan JAOCH et al.

Serial No.: 09/916,195

Filed: July 27, 2001

For: NONSTEROIDAL ANTIINFLAMMATORY AGENTS



Group Art Unit: TBA

Examiner: TBA

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Prior to initial examination and in response to the Notice to File Missing Parts mailed November 13, 2001, please amend the above-identified application as follows:


IN THE ABSTRACT:

Please add the abstract as follows:

REMARKS

The Commissioner is hereby authorized to charge any fees associated with this response or credit any overpayment to Deposit Account No. 13-3402.

Respectfully submitted,



Anthony J. Zelano 27,969
Attorney for Applicant(s)

MILLEN, WHITE, ZELANO
& BRANIGAN, P.C.

Arlington Courthouse Plaza 1, Suite 1400
2200 Clarendon Boulevard
Arlington, Virginia 22201
Telephone: (703) 243-6333
Facsimile: (703) 243-6410


Attorney Docket No.: SCH-1823

Date: December 13, 2001

K:\Sch\1823\Preliminary Amendment.doc



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/916,195	07/27/2001	Stefan Jarosh	SCH-1823

23599

MILLEN, WHITE, ZELANO & BRANIGAN, P.C.
2200 CLARENDON BLVD.
SUITE 1400
ARLINGTON, VA 22201

CONFIRMATION NO. 7080

FORMALITIES LETTER



OC00000007140193

Date Mailed: 11/30/2001



Missing Parts & / Mo. Eot
Due 12/13/01
(ABSTRACT DUE)
NOTICE OF INCOMPLETE REPLY (NONPROVISIONAL)

Filing Date Granted

The U.S. Patent and Trademark Office has received your reply on 11/13/2001 to the Notice to File Missing Parts (Notice) mailed 09/13/2001 and it has been entered into the nonprovisional application. The reply, however, does not include the following items required in the Notice.

The period of reply remains as set forth in the Notice. You may, however, obtain EXTENSIONS OF TIME under the provisions of 37 CFR 1.136 (a) accompanied by the appropriate fee (37 CFR 1.17(a)).

A complete reply must be timely filed to prevent ABANDONMENT of the above-identified application.

The required items noted below SHOULD be filed along with any items required above. The filing date of this nonprovisional application will be the date of receipt of the items required above.

- The balance due by applicant is \$.00.
- The English translation fee of \$.00 as set forth 37 CFR 1.17(k) was not paid.

The application is informal since it does not comply with the regulations for the reason(s) indicated below.

The required item(s) identified below must be timely submitted to avoid abandonment:

- * An abstract was not provided for this application. An abstract of the technical disclosure is required under 37 CFR 1.72(b).

A copy of this notice MUST be returned with the reply.

Customer Service Center

Dated 12/19/01-HP/KS



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of :

Jarocho et al.

Group Art Unit: TBA

Serial No.: 09/916,195

Examiner: TBA

Filed: July 27, 2001

For: NONSTEROIDAL ANTIINFLAMMATORY AGENTS

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents
Washington, D.C. 20231


Sir:

Prior to initial examination, please amend the above-identified application as follows:

IN THE CLAIMS:

Please amend claim 8 as follows:

8. (Amended) Process for the production of compounds of general formula I according to claim I, characterized in that an α -ketocarboxylic acid of general formula II




in which A, R¹ and R² have the meanings that are indicated in formula I,
is either optionally esterified with a compound of general formula



(III)

in which R^3 has the meaning that is indicated in general formula I, and R^{12} means a C_1-C_5 alkyl group,

in the presence of a catalyst, such as, e.g., fluoride salts or basic compounds such as alkali carbonates, or is reacted with an alkyl metal compound, for example a Grignard reagent or a lithium alkyl, to form a compound of formula IV




optionally the ester is cleaved again and then is reacted with a compound of general formula V



whereby R^{13} means a hydrogen atom of a C_1-C_5 acyl group, and Ar has the meaning that is indicated in general formula I, whereby the radical R^{13} is cleaved off or is reacted directly with a compound of general formula



whereby R^{13} means a hydrogen atom of a C_1-C_5 acyl group, and Ar has the meaning that is indicated in general formula I, optionally after activation of the acid function by, e.g., conversion into the acid chloride, whereby the radical R^{13} is cleaved off in any sequence and is reacted with a compound of general formula III




in which R^3 and R^{12} have the above-indicated meanings, in the presence of a catalyst, such as, e.g., fluoride salts or basic compounds such as alkali carbonates, or is reacted with an alkyl metal compound, for example a Grignard reagent or a lithium alkyl.

REMARKS

The amendment to the claim was made to remove the multiple dependency of the claim. It is submitted that no new matter has been added and entry of the amendment is respectfully requested.

The Commissioner is hereby authorized to charge any fees associated with this response or credit any overpayment to Deposit Account No. 13-3402.

Respectfully submitted,



Anthony J. Zelano 27,969
Attorney for Applicant(s)

MILLEN, WHITE, ZELANO
& BRANIGAN, P.C.
Arlington Courthouse Plaza 1, Suite 1400
2200 Clarendon Boulevard
Arlington, Virginia 22201
Telephone: (703) 243-6333
Facsimile: (703) 243-6410

Attorney Docket No.: SCH-1823


Date: November 13, 2001

VERSION WITH MARKINGS TO SHOW CHANGES MADE

IN THE CLAIMS:

Please amend claim 8 as follows:

8. (Amended) Process for the production of compounds of general formula I according to claim [claims] 1 [and 2], characterized in that an α -ketocarboxylic acid of general formula II




in which A, R¹ and R² have the meanings that are indicated in formula I, is either optionally esterified with a compound of general formula



in which R³ has the meaning that is indicated in general formula I, and R¹² means a C₁-C₅ alkyl group,

in the presence of a catalyst, such as, e.g., fluoride salts or basic compounds such as alkali carbonates, or is reacted with an alkyl metal compound, for example a Grignard reagent or a lithium alkyl, to form a compound of formula IV



optionally the ester is cleaved again and then is reacted with a compound of general formula V



whereby R^{13} means a hydrogen atom of a C_1-C_5 acyl group, and Ar has the meaning that is indicated in general formula I, whereby the radical R^{13} is cleaved off or is reacted directly with a compound of general formula



whereby R^{13} means a hydrogen atom of a C_1-C_5 acyl group, and Ar has the meaning that is indicated in general formula I, optionally after activation of the acid function by, e.g., conversion into the acid chloride, whereby the radical R^{13} is cleaved off in any sequence and is reacted with a compound of general formula III



in which R^3 and R^{12} have the above-indicated meanings, in the presence of a catalyst, such as, e.g., fluoride salts or basic compounds such as alkali carbonates, or is reacted with an alkyl metal compound, for example a Grignard reagent or a lithium alkyl.